A QUESTION OF AGM QUESTIONS, page-12

Can I please add a note of caution to any list put together. IMO the questions should be of a nature that Paul can realistically and meaningfully answer at the AGM given he doesn't have a crystal ball on the timing of each bureau or how a future funding would be structured.

For example, I'd like Paul to confirm the reason PAR is including BML and biomarkers (ADAMTS-5, COMP) as secondary endpoints in the Phase 3 clinical trial in order to facilitate reimbursement with health insurers based on disease modification. This to be has direct financial implications on future pricing and take-up rates.